Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-07-01
Serie:	BMC Cancer
Soggetti:	atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors
Accesso online:	https://doi.org/10.1186/s12885-025-14400-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!